ATE317398T1 - Modifiziertes e.coli enterotoxin ii signalpeptid sowie ein mikroorganismus der ein fusionsprotein sowie ein heterologes protein exprimiert - Google Patents

Modifiziertes e.coli enterotoxin ii signalpeptid sowie ein mikroorganismus der ein fusionsprotein sowie ein heterologes protein exprimiert

Info

Publication number
ATE317398T1
ATE317398T1 AT99944889T AT99944889T ATE317398T1 AT E317398 T1 ATE317398 T1 AT E317398T1 AT 99944889 T AT99944889 T AT 99944889T AT 99944889 T AT99944889 T AT 99944889T AT E317398 T1 ATE317398 T1 AT E317398T1
Authority
AT
Austria
Prior art keywords
modified
signal peptide
protein
coli enterotoxin
microorganism
Prior art date
Application number
AT99944889T
Other languages
English (en)
Inventor
Se Chang Kwon
Sung Youb Jung
Hoon Shin
Jay Do Choi
Ki Doo Choi
Gwan Sun Lee
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Application granted granted Critical
Publication of ATE317398T1 publication Critical patent/ATE317398T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • C12N15/625DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT99944889T 1998-09-15 1999-09-15 Modifiziertes e.coli enterotoxin ii signalpeptid sowie ein mikroorganismus der ein fusionsprotein sowie ein heterologes protein exprimiert ATE317398T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019980038061A KR100316347B1 (ko) 1998-09-15 1998-09-15 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법

Publications (1)

Publication Number Publication Date
ATE317398T1 true ATE317398T1 (de) 2006-02-15

Family

ID=36120918

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99944889T ATE317398T1 (de) 1998-09-15 1999-09-15 Modifiziertes e.coli enterotoxin ii signalpeptid sowie ein mikroorganismus der ein fusionsprotein sowie ein heterologes protein exprimiert

Country Status (14)

Country Link
US (1) US6605697B1 (de)
EP (1) EP1114062B1 (de)
JP (1) JP3701201B2 (de)
KR (1) KR100316347B1 (de)
CN (1) CN1144815C (de)
AT (1) ATE317398T1 (de)
AU (1) AU754435B2 (de)
BR (1) BRPI9913698B1 (de)
CA (1) CA2342537C (de)
DE (1) DE69929805T2 (de)
DK (1) DK1114062T3 (de)
NZ (1) NZ510385A (de)
RU (1) RU2198179C2 (de)
WO (1) WO2000015661A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242177B1 (en) * 1995-03-01 2001-06-05 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
KR100356140B1 (ko) 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
KR100360594B1 (ko) * 2000-01-19 2002-11-13 한미약품공업 주식회사 인간 인터페론 알파의 발현 분비벡터 및 이를 이용한인터페론 알파의 생산 방법
US7737260B2 (en) 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Protein complex using an immunoglobulin fragment and method for the preparation thereof
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
CN101505789A (zh) 2006-07-06 2009-08-12 株式会社大熊 稳定的人生长激素液体制剂
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
KR101831300B1 (ko) 2010-10-29 2018-02-23 한미사이언스 주식회사 재조합 대장균으로부터 인간 과립구 콜로니 자극인자를 정제하는 방법
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EA037848B1 (ru) 2016-07-14 2021-05-27 Общество С Ограниченной Ответственностью "Биохимический Агент" Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты)
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3806888B1 (de) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Von pde5 abgeleitete regulatorische konstrukte und verfahren zur verwendung in der immuntherapie
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
BR112021025022A2 (pt) 2019-06-12 2022-02-22 Obsidian Therapeutics Inc Composições de ca2 e métodos para regulação ajustáveis
US20220267398A1 (en) 2019-06-12 2022-08-25 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
JP2024500250A (ja) 2020-12-15 2024-01-05 アルバダ セラピューティクス インコーポレイテッド Covid-19の治療のためのdsg2組成物及び方法
CA3236070A1 (en) 2021-11-02 2023-05-11 Arvada Therapeutics, Inc. Dsg2 compositions and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0177343B1 (de) * 1984-10-05 1992-07-22 Genentech, Inc. DNA, Zellkulturen und Verfahren zur Sekretion von heterologen Proteinen und periplasmische Proteinrückgewinnung
JPS63230089A (ja) * 1987-03-18 1988-09-26 Takeda Chem Ind Ltd 分泌発現による蛋白質の製造法
JPH0479898A (ja) * 1990-07-23 1992-03-13 Kitasato Inst:The コレラ菌及び毒素原性大腸菌を同時検出するためのdna及びrnaプローブとそれらを用いたコレラ菌及び毒素原性大腸菌の検出方法
EP0626448A3 (de) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon

Also Published As

Publication number Publication date
DE69929805T2 (de) 2006-10-26
WO2000015661A1 (en) 2000-03-23
US6605697B1 (en) 2003-08-12
BRPI9913698B1 (pt) 2016-06-21
EP1114062B1 (de) 2006-02-08
CN1144815C (zh) 2004-04-07
CA2342537C (en) 2008-07-08
RU2198179C2 (ru) 2003-02-10
AU5761899A (en) 2000-04-03
DK1114062T3 (da) 2006-06-06
DE69929805D1 (de) 2006-04-20
CN1318070A (zh) 2001-10-17
BR9913698A (pt) 2002-01-29
KR100316347B1 (ko) 2002-08-27
EP1114062A1 (de) 2001-07-11
NZ510385A (en) 2002-12-20
JP3701201B2 (ja) 2005-09-28
JP2002538765A (ja) 2002-11-19
AU754435B2 (en) 2002-11-14
CA2342537A1 (en) 2000-03-23
KR20000019788A (ko) 2000-04-15

Similar Documents

Publication Publication Date Title
ATE317398T1 (de) Modifiziertes e.coli enterotoxin ii signalpeptid sowie ein mikroorganismus der ein fusionsprotein sowie ein heterologes protein exprimiert
EP1323820A3 (de) Verfahren zur Gewinnung von heterologen Polypeptiden aus Bakterienzellen
ATE421977T1 (de) Reinigung von peptiden unter verwendung von metall-ion-affinitätschromatographie
EP0824148A3 (de) Polyester-Synthase Gen und Verfahren zur Herstellung von Polyestern
EP0722461A4 (de) Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird
AU7550098A (en) System for expressing hyperthermostable protein
CA2438886A1 (en) Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture
DK0786009T3 (da) Fremgangsmåde til bakteriel fremstilling af heterologe polypeptider med disulphidbindinger
RU2001110120A (ru) Модифицированный сигнальный пептид энтеротоксина-ii e. coli и микроорганизм, экспрессирующий белок слияния упомянутого пептида с гетерологичным белком
IL141869A0 (en) Mammalian transforming growth factor beta-9 (ztgfss9)
ATE409748T1 (de) Verfahren zur herstellung sekretorischer kex2- derivate
CA2088068A1 (en) Protein structure of the plant toxin gelonin
DE69736389T8 (de) Proteine mit zellulase-aktivitäten und prozess für ihre herstellung
AU3121784A (en) Polypeptides
CA2327524A1 (en) Method of controlling cleavage by ompt protease
DK0828004T3 (da) Proteindisulfidisomerase-gen afledt af stamme af methylotrof gær
EP0750040A3 (de) Varianten des Makrophagen-stimulierendes-Proteins und Verfahren zur ihrer Herstellung
RU93032287A (ru) Способ получения окситоцина и рекомбинантные плазмидные днк ptoteilox и штаммы escherichia coli tg1/ptoteilox для его осуществления
CA2034385A1 (en) Vector to produce biologically important peptides
KR950032621A (ko) 신규한 재조합 발현벡터 및 그를 이용한 인간 알파 인터페론의 제조방법
DK0959130T3 (da) Kloning og udtrykkelse af nyt glucoamylasegen fra Endomyces fibuliger

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties